Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) is set to post its quarterly earnings results before the market opens on Monday, November 6th. Analysts expect Concert Pharmaceuticals to post earnings of ($0.54) per share for the quarter.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.04. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.20 million. Concert Pharmaceuticals had a negative return on equity of 61.98% and a negative net margin of 60,681.70%. On average, analysts expect Concert Pharmaceuticals to post $-2.04 EPS for the current fiscal year and $-2.13 EPS for the next fiscal year.

Shares of Concert Pharmaceuticals, Inc. (NASDAQ CNCE) opened at 16.65 on Monday. The company’s market capitalization is $377.74 million. The stock’s 50 day moving average price is $15.13 and its 200-day moving average price is $14.67. Concert Pharmaceuticals, Inc. has a 1-year low of $7.11 and a 1-year high of $19.11.

Several research firms recently commented on CNCE. ValuEngine raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Concert Pharmaceuticals in a research report on Friday, October 20th. BidaskClub cut Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Zacks Investment Research raised Concert Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Tuesday, September 26th. Finally, Mizuho began coverage on Concert Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $23.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $23.00.

In other news, insider Value Fund L. P. Biotechnology bought 331,916 shares of the stock in a transaction on Thursday, October 19th. The shares were bought at an average price of $15.84 per share, with a total value of $5,257,549.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ryan Lynch sold 3,500 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $14.51, for a total value of $50,785.00. Following the completion of the transaction, the insider now directly owns 9,500 shares in the company, valued at approximately $137,845. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/30/concert-pharmaceuticals-inc-cnce-scheduled-to-post-earnings-on-monday.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Earnings History for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.